IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v25y2024i5d10.1007_s10198-023-01623-5.html
   My bibliography  Save this article

Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis

Author

Listed:
  • Lorna Wills

    (Cancer Research UK
    National Cancer Registration and Analysis Service)

  • Diana Nagarwalla

    (Cancer Research UK
    National Cancer Registration and Analysis Service)

  • Clare Pearson

    (Cancer Research UK
    National Cancer Registration and Analysis Service)

  • Sean McPhail

    (National Cancer Registration and Analysis Service)

  • Rose Hinchliffe

    (Cancer Research UK)

  • Ben Sharpless

    (Cancer Research UK
    National Cancer Registration and Analysis Service)

  • Fahmina Fardus-Reid

    (Cancer Research UK
    National Cancer Registration and Analysis Service)

  • Lyndsy Ambler

    (Cancer Research UK)

  • Samantha Harrison

    (Cancer Research UK)

  • Jon Shelton

    (Cancer Research UK)

Abstract

Background The increasing burden of cancer has economic implications for the healthcare system in England. However, there is limited evidence on the cost of cancer treatment. We calculated the costs of initial cancer treatment (resection, radiotherapy, systemic anti-cancer therapy [SACT]) based on stage at diagnosis. Methods Data from England’s National Cancer Registration Dataset were matched to English Hospital, Radiotherapy and SACT data for breast, lung, prostate, colon and rectal cancers diagnosed between 2016 and 2018. Treatment data were matched to National Schedule of Reference Costs data to calculate the cost of each treatment event. Results Breast, colon and rectal cancers treated with resection, radiotherapy or SACT had increasing costs with later stage at diagnosis; costs for lung and prostate cancers were lower at stages 1 and 4 compared to stages 2 and 3. In general, surgery and SACT were the most expensive treatments. Radiotherapy and SACT costs showed little change across stages 1–3; radiotherapy costs decreased in stage 4, while SACT costs increased. Conclusions This analysis estimates initial treatment costs by stage based on observed data. Future research can build on this to provide more comprehensive costings associated with cancer; this is important for future planning of cancer services.

Suggested Citation

  • Lorna Wills & Diana Nagarwalla & Clare Pearson & Sean McPhail & Rose Hinchliffe & Ben Sharpless & Fahmina Fardus-Reid & Lyndsy Ambler & Samantha Harrison & Jon Shelton, 2024. "Estimating surgery, radiotherapy and systemic anti-cancer therapy treatment costs for cancer patients by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(5), pages 763-774, July.
  • Handle: RePEc:spr:eujhec:v:25:y:2024:i:5:d:10.1007_s10198-023-01623-5
    DOI: 10.1007/s10198-023-01623-5
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-023-01623-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s10198-023-01623-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Li Sun & Rosa Legood & Isabel dos-Santos-Silva & Shivani Mathur Gaiha & Zia Sadique, 2018. "Global treatment costs of breast cancer by stage: A systematic review," PLOS ONE, Public Library of Science, vol. 13(11), pages 1-14, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hofmarcher, Thomas & Lindgren, Peter & Wilking, Nils, 2022. "Cancer Care in Türkiye in a European Context," IHE Report / IHE Rapport 2022:10, IHE - The Swedish Institute for Health Economics.
    2. Michela Franchini & Stefania Pieroni & Edgardo Montrucchio & Jacopo Nori Cucchiari & Cosimo Di Maggio & Enrico Cassano & Brunella Di Nubila & Gian Marco Giuseppetti & Alberto Nicolucci & Gianfranco Sc, 2021. "The P.I.N.K. Study Approach for Supporting Personalized Risk Assessment and Early Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(5), pages 1-15, March.
    3. Iasmina Petrovici & Mihaela Ionica & Octavian C. Neagoe, 2021. "Economic Crisis: A Factor for the Delayed Diagnosis of Breast Cancer," IJERPH, MDPI, vol. 18(8), pages 1-10, April.
    4. Alfredo Palacios & Carlos Rojas-Roque & Lucas González & Ariel Bardach & Agustín Ciapponi & Claudia Peckaitis & Andres Pichon-Riviere & Federico Augustovski, 2021. "Direct Medical Costs, Productivity Loss Costs and Out-Of-Pocket Expenditures in Women with Breast Cancer in Latin America and the Caribbean: A Systematic Review," PharmacoEconomics, Springer, vol. 39(5), pages 485-502, May.
    5. Ian Grady & Sean Grady & Nailya Chanisheva, 2021. "Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(9), pages 1365-1370, December.
    6. Francesco Saverio Mennini & Marco Trabucco Aurilio & Simone Gazzillo & Claudia Nardone & Paolo Sciattella & Andrea Marcellusi & Raffaele Migliorini & Valerio Sciannamea & Andrea Piccioni & Matteo Bolc, 2021. "An Analysis of the Social and Economic Costs of Breast Cancer in Italy," IJERPH, MDPI, vol. 18(17), pages 1-12, August.
    7. Chunhuan Lao & Mohana Mondal & Marion Kuper-Hommel & Ian Campbell & Ross Lawrenson, 2022. "Differences in Breast Cancer Costs by Cancer Stage and Biomarker Subtype in New Zealand," PharmacoEconomics - Open, Springer, vol. 6(4), pages 539-548, July.

    More about this item

    Keywords

    Cancer; Treatment; Costs; Stage at diagnosis;
    All these keywords.

    JEL classification:

    • H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:25:y:2024:i:5:d:10.1007_s10198-023-01623-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.